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Abstract
Background: Mass drug administration (MDA) is part of the current trachoma control strategy, but it can be costly and
results in many uninfected individuals receiving treatment. Here we explore whether alternative, targeted approaches are
effective antibiotic-sparing strategies.
Methodology/Principal Findings: We analysed data on the prevalence of ocular infection with Chlamydia trachomatis and
of active trachoma disease among 4,436 individuals from two communities in The Gambia (West Africa) and two
communities in Tanzania (East Africa). An age- and household-structured mathematical model of transmission was fitted to
these data using maximum likelihood. The presence of active inflammatory disease as a marker of infection in a household
was, in general, significantly more sensitive (between 79% [95%CI: 60%–92%] and 86% [71%–95%] across the four
communities) than as a marker of infection in an individual (24% [16%–33%]–66% [56%–76%]). Model simulations, under
the best fit models for each community, showed that targeting treatment to households has the potential to be as effective
as and significantly more cost-effective than mass treatment when antibiotics are not donated. The cost (2007US$) per
incident infection averted ranged from 1.5 to 3.1 for MDA, from 1.0 to 1.7 for household-targeted treatment assuming
equivalent coverage, and from 0.4 to 1.7 if household visits increased treatment coverage to 100% in selected households.
Assuming antibiotics were donated, MDA was predicted to be more cost-effective unless opportunity costs incurred by
individuals collecting antibiotics were included or household visits improved treatment uptake. Limiting MDA to children
was not as effective in reducing infection as the other aforementioned distribution strategies.
Conclusions/Significance: Our model suggests that targeting antibiotics to households with active trachoma has the
potential to be a cost-effective trachoma control measure, but further work is required to assess if costs can be reduced and
to what extent the approach can increase the treatment coverage of infected individuals compared to MDA in different
settings.
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Introduction
Trachoma, a ‘Neglected Tropical Disease’, is the leading
infectious cause of blindness worldwide and there are currently
an estimated 46 million people with the active stage of the disease
[1]. The disease mostly affects impoverished populations where
people cannot afford treatment and access to running water is
scarce.
The World Health Organization (WHO) advocates the ‘SAFE’
strategy (Surgery for trichiasis, distribution of Antibiotics, Facial
cleanliness and Environmental improvement) to work towards the
Global Elimination of Trachoma as a public health problem by
2020. Annual mass drug administration (MDA) of antibiotics, to
reduce the prevalence of the aetiological bacterium, Chlamydia
trachomatis, is recommended for at least three years to members of
communities in which the prevalence of Trachomatous Inflam-
mation – Follicular (TF) in 1–9 year-olds is 10% or greater [2].
WHO recommends azithromycin as the first-line (oral) antibiotic
for all, except infants under the age of 6 months who are given
topical tetracycline [2]. MDA is advocated because screening
individuals is not cost-effective and there is a poor correlation
between active disease and infection of an individual [3,4,5,6].
Field-ready and cost-effective diagnostic tests for infection with C.
trachomatis are currently unavailable.
The ‘SAFE’ strategy has had success in reducing the prevalence
of active trachoma in certain populations [7,8,9]. However, there
are many costs associated with implementing MDA, particularly if
the antibiotics are not donated, and many uninfected individuals
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receive treatment [10,11,12]. It has been estimated that there are
fifty-seven countries endemic for trachoma [13]. Control pro-
grammes in eighteen of these countries currently receive
azithromycin donated by the manufacturer, Pfizer, through the
International Trachoma Initiative [14]. However a large disparity
remains in certain countries between the number of individuals in
the target population requiring treatment and the number of
individuals receiving antibiotics [14].
If antibiotics can be successfully targeted to groups of infected
individuals within a population rather than being administered to
the whole population, the number of antibiotic doses required per
population may be reduced. This saving of antibiotic resources
could be utilised by other populations who require treatment to
reduce trachoma. However the targeting method would only be
justified if the method is as effective in reducing transmission as
MDA and is also cost-effective.
Households with active trachoma are potential targets for
antibiotic distribution. Trachoma clusters by household
[15,16,17,18] and we have previously shown that in most
communities intra-household transmission is very efficient [19].
We found on average 71% of incident infections to be the result of
household transmission (with the remainder due to transmission
between households). An alternative approach to targeting
treatment would be to limit treatment to children because they
are the principal reservoir and source of infection in most
communities. Children in some communities have been shown to
have a relatively high prevalence of active disease [20,21,22] and a
high burden of infection [23].
Here we investigate whether targeting antibiotics to households
that have at least one member with active disease or to children
alone is effective in the prevention of ocular chlamydial infection
by analysing data on the prevalence of C. trachomatis and active
disease from four endemic populations in West and East Africa
(two in The Gambia, and two in Tanzania) with different baseline
trachoma prevalence. We calculate the cost-effectiveness of
targeted household treatment compared with MDA on the basis
of a mathematical model and previously published data on the
costs of these interventions [10,11].
Methods
Data Collection and Ethical Considerations
Conjunctival swabs were collected from a total of 4,436
individuals living in four endemic populations, which had not
received prior interventions for trachoma control, in West and
East Africa (Upper Saloum District and Jali village in The
Gambia; Kahe Mpya sub-village and Maindi village in Tanzania)
and the presence of infection was assessed using Polymerase Chain
Reaction (PCR) amplification of a target sequence in the common
cryptic plasmid of the bacterium C. trachomatis. Standard
procedures current at the time of these surveys were followed to
prevent contamination, described in [23] and [24]. In Maindi
village, quantitative PCR amplification of the omp1 gene was used
to indicate presence of infection. In all four studies clinical
observations were made by experienced trained observers using a
62.5 binocular loupe and pen torch or direct sunlight. In The
Gambia the more detailed clinical diagnosis ‘‘FPC’’ system [25]
was used but subsequently converted to the simplified WHO
grading system [26] for this analysis. In Tanzania the simplified
grading system was used. Active disease was defined as the
presence of TF and / or Trachomatous Inflammation – Intense
(TI). Detailed demographic information was collected including
individual age, gender, and household membership. Full descrip-
tions of the study populations and laboratory methods have been
published elsewhere [17,24,27,28] and details on community
structure are summarized in [19]. Pre-control prevalences of
infection in these populations (all ages) were 7.2%, 22.1%, 9.5%
and 36.0% respectively. The age distribution of the prevalence of
infection in these four communities is given in Table S1. The
proportion of people present and consented to being screened for
trachoma in the four data sets was 0.84 Upper Saloum district,
0.98 Kahe Mpya sub-village, 0.99 Jali village, and 0.86 for Maindi
village. The work presented in this paper is based on further
analyses of the data obtained in the original studies which had
been granted ethical clearance [17,24,27,28] and did not involve
collecting further information. For this reason additional ethical
approval was not sought.
Sensitivity and Specificity of Active Disease as Marker of
Infection
The sensitivity and specificity of active disease (TF and TI) as a
marker of infection were calculated among individuals in each
community. We also calculated the sensitivity and specificity of
active disease exhibited by at least one member of a household as a
marker for infection of at least one household member (which we
refer to as the household sensitivity and specificity).
Model of Infection Transmission
Ocular chlamydial infection probably elicits only a limited
protective immune response against re-infection and can be
described by a simple Markov model where each individual may
be either susceptible or infected. We have previously analyzed a
susceptibleRinfectedRsusceptible (SIS) model where the popula-
tion is structured into households [19,29,30]. Here we have
extended this model to allow for different transmission parameters
among ‘children’ (those aged less than ten years) and ‘adults’ (those
individuals aged 10 years and older) (Text S1 ‘Model of Ocular
Chlamydia Transmission’). We chose this classification of age because
children under the age of ten are considered to be the principal
reservoir of infection. Transmission parameters of each model for
Author Summary
Repeated ocular infection with the bacterium Chlamydia
trachomatis leads to the development of trachoma, a
major cause of infectious blindness worldwide. Mass
distribution of antibiotics, a component of the current
trachoma control strategy, has had success in reducing
infection in some areas, but results in a large number of
uninfected people receiving antibiotics. We have previ-
ously shown that transmission of the bacteria between
people in the same household is very efficient. Here, we
investigated the effectiveness and cost-effectiveness of
targeting antibiotics to households with active trachoma
(inflammatory disease) compared to mass distribution,
using data from four trachoma-endemic populations and a
mathematical model of transmission. We found a high
correspondence between households with active tracho-
ma and infected households. In all populations the
household targeted approach was predicted to be as
effective as mass distribution, but it reduced the number
of uninfected individuals receiving antibiotics, making the
targeted strategy more cost-effective when antibiotics are
not donated. Assuming antibiotics are donated, we
predicted the targeted strategy to be more cost effective
if it increases the proportion of infected individuals
receiving treatment. Further work to address the feasibility
and the cost variability in implementing the targeted
approach in different settings is now required.
Targeting Antibiotics for Trachoma Control
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each dataset were estimated from the survey data using maximum
likelihood, assuming endemic equilibrium. The most parsimonious
yet adequate model for each dataset was selected using the Akaike
Information Criterion (AIC) [31]. The transmission model was
written in R (version 2.7.2). The rate of recovery from infection
was taken as the reciprocal of the average duration of infection
estimated from a Gambian cohort with frequent follow-up [4]
(18.6 weeks for children, 7.1 weeks for adults and 17.2 weeks on
average for the non-age-structured model).
Stochastic Simulations of Treatment Scenarios
The effectiveness of different treatment strategies was assessed
using the most parsimonious model identified for each of the
communities (Text S1 ‘Model Selection’, Table S2). With the
exception of Upper Saloum district, the transmission models
included a greater contribution of children to transmission than
adults. Active disease at the household level was incorporated into
the model at each round of treatment. At the time of treatment,
each household was assigned a disease status by sampling from a
Bernoulli distribution where the probability of a household having
at least one individual with active disease was taken to be a
function of the number of infected individuals within a household
at the time of treatment. This probability function was calculated
for each dataset on the basis of the observed distribution of
infection and active disease in households of different sizes (Figure
S1).
The outcome of three annual rounds of azithromycin treatment
was investigated in all four populations as this is the number of
treatment rounds recommended by the WHO prior to re-
assessment of the prevalence of active disease when the baseline
prevalence of TF in children is greater than 10%. For a
transmission model parameterised to Maindi village, annual
rounds were predicted to result in infection returning to almost
baseline level in all strategies within one year after a treatment
round suggesting that the treatment rounds need to be more
frequent for this higher transmission setting. Therefore the effect of
six bi-annual rounds was investigated for this setting.
Stochastic simulations of the model were used to examine four
possible treatment scenarios:
a) MDA, in which the aim is to treat everyone in the community
but a certain proportion of individuals is missed;
b) Household targeted treatment (HTT) of households with one
or more members presenting with active disease in a
household but a proportion of individuals is missed;
c) HTT of households with one or more member presenting
with active disease and all members within such household
are treated;
d) MDA of children aged ,10 years only, assuming that a
certain proportion is missed.
A single treatment with azithromycin was assumed to be 95%
efficacious in clearing infection [32]. We did not explicitly model
treatment of infants aged ,6 months with topical tetracycline
instead of oral antibiotics. We assumed treatment coverage to be
80% in a), b) and d). One hundred simulations were run for each
strategy to compare the effectiveness of each strategy. Further
details of the stochastic model (written in R) are given in Text S1
‘Stochastic Simulation Model’.
Cost-Effectiveness
The cost-effectiveness of different antibiotic distribution strate-
gies (compared with the ‘doing nothing’ option) from a
government and societal perspective was assessed using previously
published cost data from Mali and Nepal [10,11] (summarised in
Table S3) and the results from the stochastic simulations. The cost
data were collected in 1998 and 2000 respectively for the studies in
Mali and Nepal. Using the most recently available consumer price
index for the two countries (2007) [33,34,35], the costs were
converted to the value of US$ in 2007. Costs included the generic
price of azithromycin per tablet, drug delivery costs per population
size, and opportunity costs (the amount of money not earned per
recipient whilst they attend the treatment campaign). Delivery
costs in the Mali study consisted of governmental (salaries and
vehicle investment) and distribution (dispatching, training of
nurses and other health workers, per diems and fuel) costs specific
to each strategy. Delivery costs in the study from Nepal were
composed of salary and transportation costs and not the training of
health workers. The delivery costs were higher for household-
targeted treatment as they accounted for the extra training and
salaries of nurses to diagnose trachoma in Mali and the increase in
transport costs in Nepal (in this study two trips per community
were assumed for this strategy: one for screening and one for
treatment). We assumed that MDA was distributed via a central
site. In agreement with the study in Mali, we assumed that
opportunity costs equal to half a day or one hour’s wages were
incurred by individuals aged$10 years receiving treatment during
MDA or HTT respectively. We assumed that individuals aged 10
years or older received an average of 3.43 azithromycin tablets
and those under the age of 10 received an average of 1.02 tablets.
(Text S1 ‘Cost Effectiveness Analysis’). One hundred stochastic
simulations were performed for each strategy in each community
and the costs were applied to the resulting simulations. The total
cost of azithromycin was calculated by multiplying the number of
individuals receiving treatment by the price per tablet and the
mean number of tablets received in that age group. The delivery
costs were scaled linearly to the size of the population in the four
endemic areas under study and were assumed to occur at each
round of treatment.
A discount rate of 3% per year was applied to all costs. Two
estimates of total drug costs, delivery costs and opportunity costs
were obtained using the two different sets of cost data and the
mean cost of the two was calculated. Cost-effectiveness was
calculated on the basis of the median effectiveness observed in the
simulations, with lower and upper bounds based on the inter-
quartile range of the simulations and the upper and lower costs
from the two cost studies.
Results
Active Disease as a Marker of Infection
In all four communities (Upper Saloum district and Jali village
in The Gambia, and Kahe Mpya sub-village and Maindi village in
Tanzania) the sensitivity of active disease as a marker of infection
was higher and specificity lower at the household level compared
with the individual level (Table 1). Limiting clinical diagnosis in a
household to children under the age of 10 years resulted in a
similar household sensitivity and specificity compared to under-
taking clinical diagnosis in all age groups (Table S4).
Stochastic Simulations
Targeting treatment to households, in which at least one
resident has active disease, was predicted to result in post-
treatment dynamics similar to MDA (Figure 1). The household-
targeted approach had a slightly higher rate of return of infection
and therefore the probability of eliminating infection five years
after the last treatment round was predicted to be somewhat lower
than the probability of eliminating infection after MDA (absolute
Targeting Antibiotics for Trachoma Control
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difference between the probabilities in each setting was 20.22,
20.04, 20.25 and 20.12 for Upper Saloum district, Jali village,
Kahe Mpya sub-village and Maindi village respectively). However
if all individuals in targeted households were treated, then the
probability of eliminating infection was predicted to greatly
increase in each setting, being greater than MDA (absolute
difference between the probability of eliminating infection after
HTT with 100% coverage within the targeted households and the
probability of eliminating infection after MDA was 0.26, 0.69,
0.07 and 0.44 respectively) (Figure 1). Limiting MDA to children
under the age of 10 years resulted in an initial decrease in the
prevalence of infection in the untreated older population (Figure
S2) but the probability of eliminating infection in the whole
community was greatly reduced compared to the other treatment
scenarios investigated (Figure 1). There was a relatively smaller
difference in effectiveness between the different treatment
scenarios in the communities with relatively low baseline
prevalence (Upper Saloum district and Kahe-Mpya sub-village)
Table 1. Sensitivity and specificity of active trachoma as a marker of infection.
Population Sensitivity Specificity
Individual level Household level Individual level Household level
Upper Saloum District, The
Gambia
0.24 [0.16–0.33] 0.79 * [0.60–0.92] 0.93 [0.92–0.96] 0.64 * [0.53–0.74]
Jali village, The Gambia 0.63 [0.57–0.70] 0.86 * [0.71–0.95] 0.95 [0.94–1] 0.77 * [0.46–0.95]
Kahe Mpya sub-village, Tanzania 0.66 [0.56–0.76] 0.80 [0.68–0.90] 0.84 [0.82–0.87] 0.58 * [0.49–0.66]
Maindi village, Tanzania 0.63 [0.57–0.69] 0.84 * [0.77–0.90] 0.74 [0.70–0.78] 0.58 * [0.47–0.68]
Results are shown for four trachoma endemic communities in West and East Africa (Upper Saloum and Jali in The Gambia, and Kahe-Mpya and Maindi in Tanzania).
Numbers in square brackets indicate 95% binomial confidence intervals. The symbol * indicates statistical significance (p,0.05) between the individual and the
household level using Fisher’s exact test.
doi:10.1371/journal.pntd.0000862.t001
Figure 1. Comparison of MDA with HTT or MDA of children ,10 years old only. The y-axis represents prevalence of ocular C. trachomatis
infection. Blue (+) – MDA with 80% coverage, Red (*) – HTT with 80% coverage, Green ({) – HTT with 100% coverage, Purple (D) – MDA of children
under the age of 10 years old with 80% coverage. Treatment rounds commence at time= 0. Upper Saloum district, Kahe Mpya sub-village and Jali
village have three annual treatment rounds, Maindi village has six biannual rounds because of the high baseline prevalence of infection. 100
stochastic simulations were run for each scenario and the median of these simulations at each time point are displayed here. The bar charts show the
probability of eliminating infection from the community for each treatment scenario. MDA=Mass drug administration. HTT =Household targeted
treatment.
doi:10.1371/journal.pntd.0000862.g001
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but HTT with 100% coverage, remained the most effective
treatment scenario.
Modifying the model to account for variation in the efficiency of
transmission among households resulted in faster return of
infection for all treatment strategies in the simulations and the
probability of eliminating infection was lower five years after the
last treatment round (Figure S3). However, the relative impact of
the different strategies remained robust to this additional
complexity.
Cost-Effectiveness
A household-targeted approach resulted in a similar number of
infected individuals receiving treatment compared with MDA, but
reduced the number of treatments given to uninfected individuals
(Figure 2A). Assuming 80% therapeutic coverage and that
azithromycin was not donated, HTT was predicted to be more
cost-effective than MDA in all four communities when including
the cost of generic azithromycin (Table 2). Assuming azithromycin
was donated, HTT was predicted to be more cost effective when
opportunity costs for individuals collecting drugs in the MDA
approach were included (Table 2). Otherwise, MDA was
estimated to be more cost effective. We did not calculate the
cost-effectiveness of targeting treatment to children because the
model simulations showed it to be the least effective of the four
treatment scenarios at controlling infection.
If a visit to a household facilitates treatment of all members,
then there was a large increase in the number of incident infections
averted compared with either MDA or targeted approaches with
80% coverage in hyperendemic settings (Figure 2B). As a result,
the household targeting strategy in which all members of diseased
households are treated was predicted to be significantly more cost-
effective in the areas with high baseline prevalence, even when
azithromycin was assumed to be donated (Table 2).
Discussion
A targeted approach for distributing azithromycin would result
in fewer antibiotic doses distributed per head of population than
MDA, thus saving medication for use by other trachoma endemic
populations in need of treatment to reach ‘the Global Elimination
of Trachoma as a public health problem by the year 2020’.
However the approach would only be warranted if it is as effective
in reducing ocular C. trachomatis prevalence in a population as
MDA and as cost-effective.
Our results have indicated that targeting antibiotics to
households with at least one member with active disease has a
similar effect to MDA in the reduction of infection. Active disease
was found not to be 100% sensitive as a marker of infection at the
household level and this explains the small differences observed
between the two strategies. However, we have shown that HTT
results in a large reduction in the number of uninfected individuals
receiving antibiotics compared to MDA (26%–51% reduction).
When antibiotics were assumed to be donated, opportunity costs
incurred by individuals taking time to collect tablets from the
MDA program resulted in HTT being more cost-effective.
Although the large majority of trachoma control programmes
currently operate using donated azithromycin, we also estimated
the cost-effectiveness of HTT assuming antibiotics were purchased
at the generic price, to give a monetary value to the amount of
antibiotic used in each strategy for the donor’s perspective of the
strategy and because some small scale programmes operating at
village levels do purchase the drug [36,37]. In this case the
dominating cost was that of the antibiotics and so HTT was
estimated to be more cost-effective.
If all members of visited households were assumed to be treated
as a result of the visit by the treatment team, a much higher chance
of eliminating infection from the community in all settings
compared with MDA was predicted. The success of this approach
will depend on the extent of household transmission and the
degree to which household visits can boost treatment coverage.
For example, in a community such as Kahe Mpya where
household transmission was estimated to be limited [19], this
approach can be hypothesised to be less effective. Baseline surveys
of the prevalence of disease could be used as an indicator for the
likely degree of household transmission, enabling the selection of
communities that would benefit from a targeted approach. A large
effort is typically required to achieve high coverage levels for MDA
control programs [38]. In contrast, analogy can be drawn with
other disease control programmes, such as vaccination for polio
and measles, in which a house-to-house strategy of administering
Figure 2. Total number of individuals receiving antibiotics and
incident infections averted for MDA compared with HTT.
Coloured bars correspond to the different communities: Blue (1) –
Upper Saloum District, Green (2) – Jali village, Black (3) – Kahe Mpya
sub-village and Red (4) – Maindi village. A) The grey bars correspond to
the total number of infected individuals receiving antibiotics and the
white bars correspond to the number of uninfected individuals
receiving antibiotics. B) The total number of incident infections averted
is from the start of treatment through to 5 years after the last round of
treatment. For both panels Upper Saloum district, Kahe Mpya sub-
village and Jali village have three annual treatment rounds, Maindi
village has six biannual rounds. 100 stochastic simulations were run for
each scenario and the median of these simulations at each time point
are displayed here. The error bars correspond to the inter-quartile
range. Therapeutic coverage is donated by g. MDA=Mass drug
administration. HTT =Household targeted treatment.
doi:10.1371/journal.pntd.0000862.g002
Targeting Antibiotics for Trachoma Control
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vaccination achieves much higher coverage than a fixed point
campaign [39,40]. Whether all household members can be
reached with a single household visit remains to be investigated
and further work is required to address whether coverage of
infected individuals can be improved with HTT at what additional
costs.
The cost per incident infection averted was greatly reduced
when 100% of targeted-household members were assumed to be
treated in areas with a relatively high prevalence of infection at
baseline (Jali and Maindi villages), both when assuming azithro-
mycin was and was not donated. In low prevalence settings the
additional benefits of treating all household members were less
apparent in our simulations because we investigated the effect of
only three annual rounds of treatment, which, in these settings,
were sufficient for any treatment scenario to have a greater than
50% chance at eliminating infection.
There are some caveats to our cost analysis: the cost data used
in the study are a decade old and the linear scaling of delivery costs
to the size of each community may not be appropriate for some
costs (for example the time taken to perform a round of HTT may
depend not only on the size but also on the geography of the
population). However, the two cost studies referred to were the
only published cost data at the time of our study that included the
full cost of HTT. We assumed that individuals aged $10yr
received a mean of 3.4 tablets whilst those aged,years received 1
tablet. This is a simplification and does not include azithromycin
suspension given to younger children and topical tetracycline given
to infants under 6 months. However, this would increase the total
cost of antibiotics further, making targeted treatment more cost-
effective.
We assumed that MDA occurred via a central site distribution.
The WHO states that MDA can be carried out either via central
site or by house to house distribution [2]. If we had assumed the
latter for MDA there would have been a smaller difference in the
distribution costs between MDA and HTT, (the only difference
would be the cost of screening for active disease) and so HTT
would have appeared more cost-effective in comparison to MDA.
We took the assumption from the Mali cost study that MDA via a
central site would result in adult antibiotic recipients having an
opportunity cost of half a day’s wages and HTT one hour’s wages.
However the WHO advises that MDA should be performed
outside of the farming season [2] to try to minimise opportunity
costs and improve the treatment coverage. In our analysis
opportunity costs had a small impact on the cost-effective estimates
but further studies could be performed to analyse what proportion
of the recipient population’s activities are interrupted by the
different treatment campaigns.
The costs involved in treatment scenarios are likely to vary from
country to country and by size of the community treated. Our
work has investigated HTT in populations of approximately 1,000
people. If such an approach were to be implemented on a district
or even country-wide scale, economies of scale will have to be
considered e.g. a large number of nurses (or volunteers) will have to
be trained for screening and there may be societal costs incurred as
such personnel may stop working on other health programmes.
Further studies are required to investigate these differences.
The delivery costs of targeting treatment to diseased households
could be reduced in a number of ways which need to be
researched further. We currently assume separate visits to
households to assess disease and provide antibiotics. Assessment
and treatment could be administered in a single visit, thereby
reducing transport and salary costs. Furthermore, village volun-
teers could be trained to assess clinical disease to reduce the costs
of ophthalmic nurses (a scheme which has been trialled with
success in Ghana [41]). We also assumed that all residents would
be screened for active disease at each round of HTT. Firstly, this
could be limited to children under the age of ten: we have shown
here that this approach has the same sensitivity as screening all
ages but the difference in cost between the two approaches
remains to be ascertained. Secondly, in practice, as soon as one
person in a household is found to have active trachoma, the
remainder of the household would not need to be screened.
Therefore the cost of HTT in this work may be an overestimate in
the higher prevalence settings where it is likely that in some
households not all residents would be required to be screened.
Further data are required to elucidate how the cost of screening for
identifying target households will vary for different levels of
prevalence and household clustering, including settings where
WHO currently recommends HTT (active trachoma prevalence
of 5%–9% in 1–9 year olds).
Data on active trachoma, analysed in this study, were collected
in a scientific setting by experienced observers. The accuracy of
trachoma grading may be more variable in a programmatic
setting. A consequence of this would be that that sensitivity and
specificity of active disease as a marker of infection at the
individual level could worsen. However, this may be less significant
at the household level, where diagnosis of just a single case of
active disease is sufficient for treatment of that household. Further
field studies would help understand the implications of trachoma
grading error on HTT.
The original analyses of the cost data from Nepal and Mali
differed from our work. The study in Nepal [11,42] compared
MDA of children to HTT of all ages. The study found the two
strategies not to be significantly different from one another in the
reduction of active disease and the costs involved (although this
could be explained in part by the low power of the study). The
original study in Mali [10] found HTT to be significantly less
effective than MDA of the whole population with respect to the
reduction of active disease prevalence one year after one round of
treatment (although the age-adjusted odds ratio for prevalence
active disease after HTT in relation to MDA was 1.56 with 95%
confidence intervals of 1.00–2.43 indicating the strategies could
have had the same outcome). The study found HTT to be more
cost-effective except in low transmission settings. A difference
between our work and the previous cost analyses is that here the
cost was calculated as a cost per incident infection averted over five
years rather than a change in point prevalence between baseline
and one time point in the previous cost analysis. Measuring the
number of infections avoided is not feasible in the field but
measuring the cost-effectiveness in this way from model simula-
tions gives a better insight into the impact of each treatment
scenario on cumulative exposure to infection and therefore the
ocular disease process.
Limiting treatment to children is another way to target
treatment. Our models predicted that the prevalence in adults
declines when children under the age of ten are treated, in
agreement with House et al. [43], but this strategy is not as effective
as MDA or HTT because the probability of eliminating infection
is reduced in all four communities. Women could be included
along with children in the target group as explored in the study in
Mali [10]. However we did not investigate this strategy because
the number of transmission parameters to be estimated would
have been too large for the size of our dataset and the prevalence
of infection did not differ largely between males and females in the
study communities (excluding Maindi) [23]. Besides, there is
considerable risk that specifically excluding adult males from
treatment schedules would jeopardise community support for drug
distribution.
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Another method to target treatment would be to ‘graduate’
communities from MDA once the prevalence of ocular C.
trachomatis infection is below a certain threshold, as suggested by
Ray and colleagues [44]. Their study predicted graduating
communities to be efficacious and drug-sparing (assuming a
diagnostic test for infection becomes available in a field-ready
format), by fitting a stochastic model allowing for heterogeneous
transmission between communities, to the Upper Saloum district
and Kahe Mpya sub-village data and a group of communities in
Ethiopia.
Therefore two separate analyses of the Tanzanian and
Gambian data sets have resulted in two different suggestions for
targeting treatment. Here we fitted and simulated under a model
of transmission which allows individuals to be infected by an
infected member of their household or community at two different
rates, specific to the setting. The Upper Saloum district contains
14 villages and this analysis grouped the villages together as one
population. The Tanzanian sub-village contains balozis (groups of
roughly 10 households that form an administrative unit) that we
also grouped together. Additional analysis would be required to
understand the relationship between within household transmis-
sion and heterogeneous community transmission where several of
the communities constitute a larger population. This would then
allow comparisons of the different targeting strategies to be made.
A recent study in Ethiopia [45] found that communities which
had received MDA with azithromycin was associated with an odds
ratio of 0.51 (0.29–0.90) for childhood (1–9 years) mortality one
year after commencement of MDA compared to children in
communities which did not receive the antibiotic. If this
phenomenon extends to other settings then the impact of HTT
with azithromycin on child mortality should be examined.
Caveats to our model of transmission have been described
previously [19]. Infection status of individuals was characterised
through PCR of ocular swabs. Standard precautions at the time of
data collection were performed to prevent contamination of
infection data (although the risk of contamination cannot fully be
ruled out due to the absence of negative field controls). Sensitivity
analysis of the assumption that each household is at equal risk of
becoming infected found that increasing the level of heterogeneity
in the household transmission parameters resulted in a faster rate
of return of infection after treatment with a lower probability of
eliminating infection for each treatment strategy. Further studies
are needed to quantify differences in households’ risk of becoming
infected. Individuals were assumed not to move from one age
group to the next but this is a reasonable simplification as the time
spent in the lower age group (ten years) by each individual is far
longer than the average duration of infection. We have assumed
that the relationship between active disease and infection remains
constant in a household after treatment. This requires further
investigation but preliminary analyses of follow-up data from
Upper Saloum District and Kahe Mpya sub-village indicates that
households with at least one person with active disease at baseline
can predict which households will contain individuals with ocular
chlamydial infection at follow-up time points more accurately than
households with active disease at follow-up.
The model did not include interventions to improve facial
cleanliness (F) or the environment (E), the interventions advocated
by WHO to accompany the distribution of antibiotics [2]. The
exclusion of these interventions allowed the predicted effectiveness
and cost-effectiveness of the different distribution strategies to be
shown clearly. Inclusion of ‘F’ and ‘E’ would reduce the rate of
return of infection and increase the probability of eliminating
infection by an uncertain factor but is unlikely to alter the rank
order of the impact of the different distribution strategies. If the
cost of implementing ‘F’ and ‘E’ is independent of the antibiotic
distribution strategy then the relative differences between the cost-
effectiveness of implementing trachoma control for different
antibiotic distribution strategies would remain unchanged. The
exclusion of ‘F’ and ‘E’ from the model may explain why infection
was observed to return relatively slowly in Maindi village following
two rounds of treatment whereas our model predicts infection to
rapidly return for an area with such a high baseline prevalence of
infection. Changes in hygiene could have arisen in the village
through residents receiving radio broadcasts by the National
Trachoma Control Programme informing individuals to improve
face washing and latrine usage [46] or alternatively, by simply the
presence of the intervention itself, altering individuals’ behaviour.
Our model suggests that targeting treatment to households that
have at least one resident with active trachoma is as effective as
MDA in a diverse variety of settings and can be more effective if
the strategy increases the coverage of infected individuals. We also
show that HTT is drug-sparing and has the potential to be more
cost-effective but to have a better understanding of this in settings
for which azithromycin is donated, more studies are required to
evaluate whether HTT can improve antibiotic coverage levels of
infected individuals and whether the cost can be further reduced
compared with costs recorded in the studies in Mali and Nepal.
The results of these studies will provide a better understanding of
efficient and effective antibiotic distribution approaches for
trachoma control programmes in countries with limited resources.
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Figure S1 The probability of a household having one or more
members with active disease, given a certain number of infected
individuals, calculated for the four endemic populations.
Found at: doi:10.1371/journal.pntd.0000862.s001 (0.59 MB EPS)
Figure S2 Reduction in prevalence of ocular C. trachomatis
infection in adults and children when only children ,10 years
receive MDA. The transmission parameters used were those
estimated by fitting the model to the data from the respective
communities. The lines are median values of 100 stochastic
simulations. The black line corresponds to prevalence in ‘children’
,10 years and the grey line corresponds to ‘adults’, aged $10
years old.
Found at: doi:10.1371/journal.pntd.0000862.s002 (0.66 MB EPS)
Figure S3 Role of heterogeneity in household transmission
parameters for controlling infection. Blue - Mass treatment with
80% coverage, Red - Treatment targeted at households with one
or more individuals with active disease but 80% of individuals in
each household receive treatment, Green - Treatment targeted at
households with one or more individuals with active disease and
100% of individuals in each household are treated, Purple - MDA
of children under the age of 10 years old with 80% coverage.
Treatment rounds occur at times = 0, 1 and 2. The model fitted to
Jali village was used as an example as it has reasonably high
baseline prevalence and a large amount of household transmission.
The bar chart shows the probability of eliminating infection after
three rounds of household targeted treatment for communities
with varying levels of heterogeneity of household susceptibility.
Slight heterogeneity corresponds to an overdispersion parameter
of 5 and strong heterogeneity corresponds to an overdispersion
parameter of 1.5.
Found at: doi:10.1371/journal.pntd.0000862.s003 (0.89 MB EPS)
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numbers in the square brackets are 95% binomial confidence
intervals.
Found at: doi:10.1371/journal.pntd.0000862.s004 (0.03 MB
DOC)
Table S2 Comparison of Different Trachoma Transmission
Models Fitted to Infection Data.
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Table S3 Cost Data from Mali and Nepal summarised from
[10] and [11].
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Table S4 Sensitivity (a) and specificity (b) of active disease as a
marker of infection in the household (both limiting clinical
diagnosis to children under 10 years old and assessing clinical
disease in all ages) for four trachoma endemic communities.
Numbers in square brackets indicate 95% binomial confidence
intervals. There is no statistical significant difference between
assessing active disease in children under ten years old and
assessing disease in all ages (Fisher’s exact test p.0.05).
Found at: doi:10.1371/journal.pntd.0000862.s007 (0.03 MB
DOC)
Table S5 Maximum likelihood estimates of the transmission
parameters for each of the four populations and nested models.
The numbers in square brackets denote 95% confidence intervals.
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Text S1 Extra information of the methods: Model of Ocular
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Stochastic simulation and cost-effectiveness analysis.
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